Vyne Historical Cash Flow
| VYNE Stock | USD 3.18 0.05 1.55% |
Analysis of Vyne Therapeutics cash flow over time is an excellent tool to project Vyne Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 5.6 M or Change In Working Capital of 63 K as it is a great indicator of Vyne Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Vyne Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vyne Therapeutics is a good buy for the upcoming year.
Vyne |
About Vyne Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Vyne balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Vyne's non-liquid assets can be easily converted into cash.
Vyne Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Vyne Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Vyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.At present, Vyne Therapeutics' Change In Working Capital is projected to decrease significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 34.8 M, whereas Free Cash Flow is forecasted to decline to (26.6 M).
Vyne Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Vyne Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vyne Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (18.7M) | 13.8M | (15.6M) | (11.9M) | (301K) | (286.0K) | |
| Stock Based Compensation | 6.7M | 18.1M | 8.1M | 4.3M | 3.3M | 5.6M | |
| Free Cash Flow | (65.1M) | (137.2M) | (56.4M) | (29.2M) | (25.3M) | (26.6M) | |
| Change In Working Capital | 1.9M | (40.3M) | 4.8M | 2.3M | 60K | 63K | |
| Begin Period Cash Flow | 49.5M | 44.6M | 58.4M | 42.9M | 31.0M | 34.8M | |
| Other Cashflows From Financing Activities | 68.3M | 169K | 228K | 183K | (427K) | (405.7K) | |
| Other Non Cash Items | (691K) | 84.1M | 2.5M | (12.6M) | (254K) | (241.3K) | |
| Total Cash From Operating Activities | (65.1M) | (137.1M) | (56.4M) | (29.2M) | (25.3M) | (26.6M) | |
| Net Income | (73.7M) | (255.6M) | (73.3M) | (23.2M) | (28.5M) | (29.9M) | |
| Total Cash From Financing Activities | 5.0M | 61.8M | 39.8M | 1.7M | 82.4M | 50.6M | |
| End Period Cash Flow | 30.8M | 58.4M | 42.9M | 31.0M | 30.7M | 36.8M | |
| Investments | 41.4M | 89.1M | 1.0M | 15.7M | 5.0M | 9.0M | |
| Total Cashflows From Investing Activities | 41.9M | 89.1M | 1.0M | 15.7M | 18.0M | 24.9M | |
| Depreciation | 700K | 341K | 109K | 72K | (255K) | (242.3K) | |
| Change To Operating Activities | (389K) | (4.2M) | (371K) | (349K) | (314.1K) | (329.8K) | |
| Change To Netincome | 4.8M | 158.5M | 12.1M | (8.3M) | (9.6M) | (9.1M) | |
| Change To Liabilities | 18.1M | (13.0M) | (2.7M) | (8.7M) | (7.8M) | (7.4M) | |
| Change To Inventory | 2.8M | (1.4M) | (6.0M) | 113K | 97K | 0.0 | |
| Change To Account Receivables | 1.4M | (17.1M) | 7.7M | 11.2M | 405K | 556.6K | |
| Issuance Of Capital Stock | 4.5M | 61.6M | 76.0M | 1.7M | 366K | 347.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.